Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1978 4
1979 1
1980 2
1981 1
1985 1
1986 2
1987 3
1988 2
1989 1
1990 1
1991 3
1992 6
1993 3
1994 4
1996 1
1997 4
1998 10
1999 2
2000 3
2001 3
2003 1
2004 3
2005 4
2006 4
2007 3
2008 4
2009 5
2010 10
2011 7
2012 7
2013 10
2014 8
2015 10
2016 8
2017 12
2018 13
2019 12
2020 15
2021 10
2022 14
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group. Kennedy NA, et al. Lancet Gastroenterol Hepatol. 2019 May;4(5):341-353. doi: 10.1016/S2468-1253(19)30012-3. Epub 2019 Feb 27. Lancet Gastroenterol Hepatol. 2019. PMID: 30824404
In multivariable analysis, the only factor independently associated with primary non-response was low drug concentration at week 14 (infliximab: odds ratio 0.35 [95% CI 0.20-0.62], p=0.00038; adalimumab: 0.13 [0.06-0.28], p<0.0001); the optimal week 14 drug conce …
In multivariable analysis, the only factor independently associated with primary non-response was low drug concentration at week 14 (inflixi …
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, McDonald TJ, Lees CW, Cummings JRF, Parkes M, Mansfield JC, Irving PM, Barrett JC, McGovern D, Goodhand JR, Anderson CA, Ahmad T; PANTS Consortium. Sazonovs A, et al. Gastroenterology. 2020 Jan;158(1):189-199. doi: 10.1053/j.gastro.2019.09.041. Epub 2019 Oct 7. Gastroenterology. 2020. PMID: 31600487 Free article.
RESULTS: The HLA-DQA1*05 allele, carried by approximately 40% of Europeans, significantly increased the rate of immunogenicity (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.60-2.25; P = 5.88 10(-13)). The highest rates of immunogenicity, 92% at 1 year, were obs …
RESULTS: The HLA-DQA1*05 allele, carried by approximately 40% of Europeans, significantly increased the rate of immunogenicity (hazard ratio …
Comparing Total Keratometry Measurement on the IOLMaster 700 With Goggin Nomogram Adjusted Anterior Keratometry.
LaHood BR, Goggin M, Beheregaray S, Andrew NH, Esterman A. LaHood BR, et al. J Refract Surg. 2018 Aug 1;34(8):521-526. doi: 10.3928/1081597X-20180706-01. J Refract Surg. 2018. PMID: 30089181
PURPOSE: To compare "total keratometry" measurements with Goggin nomogram adjusted anterior keratometry (GNAK) for toric intraocular lens calculation. ...Absolute and signed steep axis of astigmatism was statistically significantly different for GNAK and total keratometry …
PURPOSE: To compare "total keratometry" measurements with Goggin nomogram adjusted anterior keratometry (GNAK) for toric intraocular …
Evaluation of statistical correction strategies for corneal back surface astigmatism with toric lenses: a vector analysis.
Langenbucher A, Hoffmann P, Cayless A, Wendelstein J, Szentmáry N. Langenbucher A, et al. J Cataract Refract Surg. 2024 Apr 1;50(4):385-393. doi: 10.1097/j.jcrs.0000000000001370. J Cataract Refract Surg. 2024. PMID: 38015426
From IOLM/CASIA keratometry, the average difference in C0 was 0.39/0.32 diopter (D). After correction with the Abulafia-Koch, Goggin, La Hood, and Castrop nomograms, it was -0.18/-0.24 D, 0.27/0.18 D, 0.13/0.08 D, and 0.17/0.10 D. ...CONCLUSIONS: The Abulafia-Koch method o …
From IOLM/CASIA keratometry, the average difference in C0 was 0.39/0.32 diopter (D). After correction with the Abulafia-Koch, Goggin, …
Outcome of adjustment for posterior corneal curvature in toric intraocular lens calculation and selection.
Goggin M, van Zyl L, Caputo S, Esterman A. Goggin M, et al. J Cataract Refract Surg. 2016 Oct;42(10):1441-1448. doi: 10.1016/j.jcrs.2016.10.004. J Cataract Refract Surg. 2016. PMID: 27839598
PURPOSE: To evaluate the accuracy of the cylinder power choice and the astigmatic refractive outcome for toric intraocular lenses (IOLs), the cylinder power of which was calculated using the Goggin nomogram that allows for the likely effect of posterior corneal astigmatism …
PURPOSE: To evaluate the accuracy of the cylinder power choice and the astigmatic refractive outcome for toric intraocular lenses (IOLs), th …
Comparison of astigmatic prediction errors associated with new calculation methods for toric intraocular lenses.
Ferreira TB, Ribeiro P, Ribeiro FJ, O'Neill JG. Ferreira TB, et al. J Cataract Refract Surg. 2017 Mar;43(3):340-347. doi: 10.1016/j.jcrs.2016.12.031. J Cataract Refract Surg. 2017. PMID: 28410715
For the Holladay toric calculator, the centroid prediction error was 0.40 @ 168, which was reduced by the Baylor nomogram (0.35 @ 169), the Abulafia-Koch formula (0.25 @ 158), and the Goggin coefficient of adjustment (0.38 @ 170). The Barrett calculator and the newly intro …
For the Holladay toric calculator, the centroid prediction error was 0.40 @ 168, which was reduced by the Baylor nomogram (0.35 @ 169), the …
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA; CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group; Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE. Ortigoza MB, et al. JAMA Intern Med. 2022 Feb 1;182(2):115-126. doi: 10.1001/jamainternmed.2021.6850. JAMA Intern Med. 2022. PMID: 34901997 Free PMC article. Clinical Trial.
The cOR for the primary outcome adjusted for site, baseline risk, WHO score, age, sex, and symptom duration was 0.94 (95% credible interval [CrI], 0.75-1.18) with posterior probability (P[cOR<1] = 72%); the cOR for the secondary adjusted outcome was 0.92 (95% CrI, 0.74- …
The cOR for the primary outcome adjusted for site, baseline risk, WHO score, age, sex, and symptom duration was 0.94 (95% credible interval …
Cluster-Randomized, Crossover Trial of Head Positioning in Acute Stroke.
Anderson CS, Arima H, Lavados P, Billot L, Hackett ML, Olavarría VV, Muñoz Venturelli P, Brunser A, Peng B, Cui L, Song L, Rogers K, Middleton S, Lim JY, Forshaw D, Lightbody CE, Woodward M, Pontes-Neto O, De Silva HA, Lin RT, Lee TH, Pandian JD, Mead GE, Robinson T, Watkins C; HeadPoST Investigators and Coordinators. Anderson CS, et al. N Engl J Med. 2017 Jun 22;376(25):2437-2447. doi: 10.1056/NEJMoa1615715. N Engl J Med. 2017. PMID: 28636854 Free article. Clinical Trial.
Patients in the lying-flat group were less likely than patients in the sitting-up group to maintain the position for 24 hours (87% vs. 95%, P<0.001). In a proportional-odds model, there was no significant shift in the distribution of 90-day disability outcomes on the gl …
Patients in the lying-flat group were less likely than patients in the sitting-up group to maintain the position for 24 hours (87% vs. 95%, …
204 results